FLT3突变型急性髓性白血病的靶向治疗药物吉列替尼

Targeted Medicine Gilteritinib for Acute Myeloid Leukemia Patients with FLT3 Mutation

吉列替尼于2018年11月28日获美国食品药物管理局(FDA)批准用于治疗有FLT3突变的复发或难治性急性髓性白血病。FDA对该药物的Ⅲ期临床试验进行了中期分析,该文对吉列替尼针对的靶点及药物临床前、临床试验的结果进行了综述,以促进合理使用该药物。

On November 28,2018,the Food and Drug Administration of U. S. approved gilteritinib for the treatment of relapsed or refractory acute myeloid leukemia( AML) with a FLT3 mutation. The FDA approval of gilteritinib was based on an interim analysis of the ADMIRAL trial( phase Ⅲ) . In this review,the targets targeted by gilteritinib and the results of preclinical and clinical trials of gilteritinib were reviewed to promote rational use of the drug.